Key Takeaways
- • Midwest Products & Engineering (MPE), a Milwaukee-based medical device manufacturer, has been sold by current owner Beecken Petty O'Keefe & Company (BPOC), a Chicago-based private equity firm, to Graham Partners, a Pennsylvania-based PE firm specializing in industrial technology.
- • Graham Partners, headquartered in Newton Square, Pennsylvania, acquired MPE as part of its strategic focus on industrial technology investments, signaling continued consolidation in the medical device manufacturing sector.
- • The transaction represents a secondary buyout, with BPOC exiting its investment in MPE and transferring ownership to a larger or more strategically aligned private equity operator.
Summary
Midwest Products & Engineering (MPE), a Milwaukee-based medical device manufacturer, has been sold to Graham Partners, a Newton Square, Pennsylvania-based private equity firm, according to a press release issued on Tuesday, April 7, 2026. The transaction marks an exit for Beecken Petty O'Keefe & Company (BPOC), a Chicago-based private equity firm that previously held MPE as a portfolio company.
Graham Partners, which focuses on industrial technology and related investments, acquired MPE as part of its ongoing strategy to build positions in specialized manufacturing and medical device sectors. The sale represents a secondary transaction typical of private equity markets, where initial investors divest holdings to later-stage or larger PE operators seeking geographic consolidation or operational synergies.
The limited disclosure in the announcement—including the absence of deal valuation, transaction timing, and strategic rationale from Graham Partners—suggests either confidentiality provisions common in mid-market PE transactions or minimal public visibility for the specific terms. No information regarding management continuity, operational changes, or post-acquisition plans has been disclosed to date.
Graham Partners, which focuses on industrial technology and related investments, acquired MPE as part of its ongoing strategy to build positions in specialized manufacturing and medical device sectors. The sale represents a secondary transaction typical of private equity markets, where initial investors divest holdings to later-stage or larger PE operators seeking geographic consolidation or operational synergies.
The limited disclosure in the announcement—including the absence of deal valuation, transaction timing, and strategic rationale from Graham Partners—suggests either confidentiality provisions common in mid-market PE transactions or minimal public visibility for the specific terms. No information regarding management continuity, operational changes, or post-acquisition plans has been disclosed to date.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.